Health supplement company focusing on protecting, restoring and regaining a healthier body and mind through production and distribution of medical mushrooms Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYFC) announced having commenced pre-clinical trial study of its key proprietary extract Amanita Muscaria (AME-1).
The pre-clinical trial will consist of a conditioned placement preference study (CPP) put in place to find out the adverse effects or any beneficial properties of AME-1, this will provide much needed data to establish if the extract has any abuse potential.
The CPP method is mostly used in medical field like neuroscience research, behavioral science and pharmacology to establish whether consumption of various substances can foster psychological or physical dependence.
The company’s chief operating officer, David Shisel, says the study will compare basic properties of the association of AME-1 treatment with respect to a specific environment with the association of a different environment without AME-1.
“In conjunction with the other studies the Company is conducting, this trial will bolster Psyched’s toxicological assessment of AME-1 and provide critical knowledge of any behavioral and neurological functional changes in a scientific setting. This is another key step in determining a safe dose of AME-1 for human consumption and moves Psyched closer to being able to bring our Amanita-based CPG products to market,” said the COO.
